Yili Huang, DO
Interventional Cardiology · Elmhurst, NYNPI 1093967184
Payments from drug & device makers
Across 1,670 payments — averaging $420.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$353K
- Esperion Therapeutics, Inc.$142K
- Angiodynamics, Inc.$41K
- Amarin Pharma, Inc.$40K
- AstraZeneca$33K
- Bayer$23K
- plus $68K from 54 others
Across 1 payment — averaging $1605.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$2K
What the payments were for
- Consulting fees$6,3001%
- Speaking & faculty fees$559,39580%
- Travel & lodging$28,3134%
- Food & beverage$67,00310%
- Education$1030%
- Other$37,9175%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$349,539
- NEXLETOL$140,169
- NEXLIZET$139,739
- Vascepa$39,226
- Auryon Laser System 100-120 Vac$38,679
- FARXIGA$30,950
- Kerendia$21,746
- NURTEC ODT$19,495
- Diamondback Peripheral$2,381
- Resolute$2,270
- Veltassa$2,125
- EMBLEM$1,213
- MULTAQ$1,050
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$985
- GENERAL - THERAPIES$949
- ONYX FRONTIER$943
- LUX-Dx Insertable Cardiac Monitor$792
- Peripheral Orbital Atherectomy System$785
- (6574) Coronary Other$687
- SYMPLICITY G3$645
How this compares
$701,731 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 1,603 | $1,471,188 |
| VascepaIcosapent Ethyl | 1,448 | $838,967 |
| Diclofenac Epolamine | 460 | $449,679 |
| KerendiaFinerenone | 426 | $424,463 |
| EliquisApixaban | 404 | $402,316 |
| EntrestoSacubitril/Valsartan | 332 | $325,439 |
| BrilintaTicagrelor | 350 | $307,567 |
| FarxigaDapagliflozin Propanediol | 339 | $294,488 |
| CreonLipase/Protease/Amylase | 237 | $257,577 |
| NexlizetBempedoic Acid/Ezetimibe | 452 | $214,204 |
| Repatha SureclickEvolocumab | 361 | $205,682 |
| OzempicSemaglutide | 161 | $154,838 |
| MultaqDronedarone Hcl | 105 | $112,465 |
| RybelsusSemaglutide | 67 | $108,836 |
| LinzessLinaclotide | 169 | $98,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $353,062 | $1,471,1881,603 claims |
| AstraZenecaBrilinta, Farxiga, Breztri Aerosphere | $33,374 | $663,944788 claims |
| PfizerEliquis, Nurtec Odt | $1,708 | $482,636458 claims |
| BayerKerendia | $22,990 | $424,463426 claims |
| AbbVieCreon, Linzess, Restasis | $350 | $407,689474 claims |
| NovartisEntresto | $615 | $325,439332 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $142,334 | $276,332572 claims |
| Novo NordiskOzempic, Rybelsus | $448 | $263,674228 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $33 | $142,589381 claims |
| Sanofi-aventis U.S. LLCMultaq | $1,194 | $112,465105 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $135 | $110,007231 claims |
| MerckVerquvo, Januvia | $550 | $97,001111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Elmhurst
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.